News
07-13-2017, 11:03 AM
A ground-breaking new class of oral drugs for treating breast cancer, known as cyclin-dependent kinase (CDK) inhibitors, are generally well-tolerated, with a manageable toxicity profile for most patients.
More... (http://www.news-medical.net/news/20170713/Ground-breaking-new-breast-cancer-drugs-have-manageable-toxicity-profile-for-most-patients.aspx)
More... (http://www.news-medical.net/news/20170713/Ground-breaking-new-breast-cancer-drugs-have-manageable-toxicity-profile-for-most-patients.aspx)